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in cardiovascular medicine. Acupuncture and especially “electro-
acupuncture” has wonderful placebo capabilities. Positive effects
from acupuncture can be attributed to psychosomatic mechanisms
related to conditioning, expectation, suggestion, and distraction
from the actual source of the pain or discomfort. Acupuncture, like
much of Chinese medicine, is based on mysticism—belief in that
which cannot be proven and unable to be understood.
In summary, there is no place for complementary medicine in
cardiovascular medicine.
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REPLY
In his letter to the editor regarding our document on “Integrating
Complementary Medicine Into Cardiovascular Medicine” (1), Dr.
Bartecchi states complementary medicine has no place in cardio-
vascular medicine. “No place for it?” This is not our choice in that
more than a majority of patients already are using complementary
and alternative medicine (CAM) therapy. In fact, over 50% of all
Americans are seeking the help of an alternative health care
practitioner, which in past years has represented over 600 million
visits and nearly $40 billion. Consequently, our effort with this
document was to put the emerging area of CAM treatment and
investigation into focus in order to enable the physician to provide
better patient care in a meaningful and safe manner. Whether the
physician believes or does not believe in CAM, it is important that
he or she is familiar with CAM so as to provide complete care to
the patient and be aware of many good and bad interactions, such
as with various supplements and herbs.
The “free ride” of CAM is a fact for most medical therapeu-
tics—a minority of clinical practices are actually supported by class
IA guidelines. Our intent is to stimulate more rigorous and
informative research investigations of the safety and effectiveness
of CAM therapies in cardiovascular care, with an emphasis on
safety.
At the present time, chelation therapy is neither proven nor
unproven, and there may be dangers. Clearly, this area deserves a
careful randomized study now in progress (TACT) and sponsored
by the National Institutes of Health (NIH) in order to resolve the
role of chelation therapy.
Dr. Bartecchi criticizes acupuncture, stating that electro-
acupuncture has wonderful placebo capabilities, and positive effects
of acupuncture can be related to psychosomatic mechanisms—
opinions that are not only not referenced but also unfounded.
Clearly, all treatments in medicine, whether allopathic or integra-
tive, have a placebo component that can contribute to as much as
30% to 40% of a clinical response. Our document provides
evidence supporting a neurophysiologic basis for the influence of
acupuncture in a number of diseased conditions including pain,
nausea and vomiting, and certain cardiovascular conditions such as
hypertension and myocardial ischemic symptoms, including angina
pectoris. These studies support a role for the endogenous opioid
system and other modulatory neurotransmitters that are activated
by acupuncture and inhibit the action of excitatory neurotransmit-
ters such as glutamate in regions of the brain concerned with
cardiovascular regulation. These regions include the rostral-
ventral-lateral medulla, the periaqueductal gray, and the arcuate
nucleus, among others. Electro-acupuncture causes very similar
effects to manual acupuncture as shown recently in the Journal of
Applied Physiology. Instead of quoting reports published by the
Scientific Review of Alternative Medicine, which, in fact, performs
no independent scientific study of this emerging area of medicine,
we would strongly encourage Dr. Bartecchi to review the high-
quality scientific literature that has been published on the mech-
anisms by which acupuncture can regulate the cardiovascular
system. Such studies are supported by the National Institutes of
Health, the Heart, Lung, and Blood Institute, and have been
published in journals such as Circulation; The American Journal of
Physiology; The Journal of Applied Physiology; Neuroscience; Brain
Research; and Autonomic Neuroscience: Basic & Clinical.
We appreciate the comments by Dr. Cheng regarding the
Chinese herbal drug danshen. We were not able to include
everything in our first document, but clearly it is important to
understand that danshen may affect hemostasis, including inhibi-
tion of platelet aggregation, interference with extrinsic blood
coagulation and antithrombin III-like activity, and promotion of
fibrinolytic activities. Certainly patients receiving warfarin therapy
may present with gross over-anticoagulation and bleeding compli-
cations with danshen, and because of these effects it should be
avoided in patients taking warfarin or antiplatelet drugs.
In our report we made a strong effort to familiarize physicians
with the actions of various herbs and supplements, not only in their
benefits, but also the many dangers and interactions that can occur
and with which the physician should be familiar. Unfortunately,
various surveys have indicated that many patients do not share the
information as to the herbs and supplements they are taking
because they feel the physician is not interested. Consequently,
because of this, various dangers, interactions, and consequences
have occurred. It is important for the physician to inquire of
patients about all medications they are taking, including herbs and
supplements. See Appendix 5 in the document on www.acc.org.
In summary, as stated in our document, our purpose has been to
familiarize cardiologists with widely employed complementary
medical practices. For the most part, our document is neither an
endorsement nor a recommendation of specific practices; rather, it
is a resource for those practitioners wishing to learn about these
techniques, and, thus, enable them to provide meaningful solid
doctor–patient relationships with a commitment to the core
mission of caring for patients on a physical, mental, and spiritual
level.
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Does Percutaneous Closure
of the Left Atrial Appendage
Prevent Stroke in Atrial Fibrillation?
With great interest we read the study by Ostermayer et al.
concerning percutaneous left atrial appendage (LAA) occlusion
using the PLAATO (percutaneous left atrial appendage trans-
catheter occlusion) system in 111 patients with atrial fibrillation
(AF) (1). Although this technique seems very attractive, several
concerns remain.
1. The investigators state that the PLAATO device has been
shown to be safe and effective in animal experiments. How-
ever, long-term results are still lacking because follow-up data in
6 of 25 dogs of the initial study have not yet been published (2).
2. Transient ischemic attack (TIA) or stroke or embolic risk
factors were criteria for patient inclusion. Thus, it remains
unclear why only stroke and not TIA was regarded a primary
or secondary end point. Were all patients investigated by a
neurologist to look for TIA and stroke at the follow-up visits?
3. When assessing angiographically the adequacy of LAA occlu-
sion, why did the researchers use the proximal and not the
distal dye flow, which appears to be the more logical approach?
Apparently both methods were used, but did they yield the
same results? Why was LAA occlusion assessed as “successful”
also in cases with “mild” or “trace” leaks? The investigators do
not exactly state in how many patients complete LAA occlu-
sion was achieved using the angiographic method.
4. Evaluating the adequacy of LAA occlusion by echocardiogra-
phy, it again remains unclear why mild and trace leaks were
defined as “successful” as it is known from surgical studies that
an incompletely occluded LAA may facilitate thrombus for-
mation and eventually embolism. The data do not show in how
many cases leak size increased, decreased, or if new leaks
developed. Did patients with leaks immediately after the
procedure or during follow-up receive oral anticoagulation?
Overall, complete LAA occlusion was present in only 35% of
patients at one month and 34% at six months, respectively.
5. The 6.6% annual mortality is quite high and exceeds the 4%
found in a previous observational AF study (3). An oversized
PLAATO device owing to its proximity may impair flow in
the circumflex branch of the left coronary artery. Furthermore,
the LAA has hemodynamic and endocrine properties, and
LAA elimination may aggravate heart failure (4). More de-
tailed information about the cardiac deaths, therefore, would
be desirable.
6. Despite “successful” LAA closure, two strokes and three TIAs
occurred. Thus, the annual event rate for stroke and TIA is
5.5%. Because AF is associated with a prothrombotic state (5),
just by closing the LAA not all sites of thrombus formation are
eliminated. In addition, one patient required surgery, and nine
procedure-related serious adverse events occurred in seven
patients, resulting in a complication rate of 6% to 7%.
Overall, the advantage of the PLAATO system in patients with
AF and a contraindication for anticoagulant therapy has not at all
been proven. Because long-term results are lacking, PLAATO at
present cannot be recommended as an alternative to oral anti-
coagulation in AF patients.
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REPLY
We appreciate the interest of Dr. Stöllberger and colleagues in
transcatheter left atrial appendage (LAA) occlusion using the
PLAATO (percutaneous left atrial appendage transcatheter occlu-
sion) system (1). They have raised a number of issues that are
answered below.
1. The 12-month results of the remaining six dogs that were still
alive at the time the initial animal experience was published
confirmed the short-term findings regarding clinical status,
and fluoroscopic, echocardiographic, and macroscopic exami-
nations (Nakai T, personal communication, August 28, 2005).
2. The intention of LAA occlusion is stroke prevention in atrial
fibrillation (AF) patients who are at high risk for ischemic
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